Abstract
Prostate cancer is a significant health problem for men in the United States. While useful treatment modalities are available, their therapeutic efficacies are limited and severe side effects remain a concern. Alternatively, immunotherapy represents one of the most valuable treatments by inducing immune response targeting tumor cells. Sipuleucel-T is the only FDA approved immunotherapeutic agent for the treatment of patients with metastatic castration-resistant prostate cancer. Overall survival benefit with sipuleucel-T is modest, and the research field of cancer immunotherapy is continuously expanding. Numerous methods designed to induce tumor-specific immunity are at various developmental stages in clinical and preclinical studies. Among such modalities, the use of adenovirus vector (Ad) as an immunotherapy agent to deliver tumor-associated antigens is an attractive and versatile vector system. In this review, we describe the potential use of Ad-vector for prostate cancer immunotherapy.
Keywords: Prostate cancer vaccine, adenovirus vaccine, immunotherapy
Current Cancer Therapy Reviews
Title:Adenovirus-based Immunotherapy for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Seema Dubey, Peter VanVeldhuizen and Dev Karan
Affiliation:
Keywords: Prostate cancer vaccine, adenovirus vaccine, immunotherapy
Abstract: Prostate cancer is a significant health problem for men in the United States. While useful treatment modalities are available, their therapeutic efficacies are limited and severe side effects remain a concern. Alternatively, immunotherapy represents one of the most valuable treatments by inducing immune response targeting tumor cells. Sipuleucel-T is the only FDA approved immunotherapeutic agent for the treatment of patients with metastatic castration-resistant prostate cancer. Overall survival benefit with sipuleucel-T is modest, and the research field of cancer immunotherapy is continuously expanding. Numerous methods designed to induce tumor-specific immunity are at various developmental stages in clinical and preclinical studies. Among such modalities, the use of adenovirus vector (Ad) as an immunotherapy agent to deliver tumor-associated antigens is an attractive and versatile vector system. In this review, we describe the potential use of Ad-vector for prostate cancer immunotherapy.
Export Options
About this article
Cite this article as:
Dubey Seema, VanVeldhuizen Peter and Karan Dev, Adenovirus-based Immunotherapy for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040264
DOI https://dx.doi.org/10.2174/1573394711208040264 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
Current Medicinal Chemistry - Anti-Cancer Agents Interferon Therapy in Lung Cancer: Current Perspectives
Current Cancer Therapy Reviews Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Editorial (Metastases Prevention is the Cure)
Current Cancer Therapy Reviews Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interaction and Structural Modification of Topoisomerase IIα by Peptidyl Prolyl Isomerase, pin1: An In Silico Study
Protein & Peptide Letters Highlights on Medical Treatment of Uterine Fibroids
Current Pharmaceutical Design NF-κB Signaling: Multiple Angles to Target OA
Current Drug Targets 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets Cancer and Stem Cells
Current Cancer Therapy Reviews Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
Current Topics in Medicinal Chemistry Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Current Trends in the Application of Nanoparticles in Drug Delivery
Current Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Crosstalk between Gut Microbiota and Central Nervous System: A Focus on Alzheimer's Disease
Current Alzheimer Research